Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Quick facts

Phase 2 pipeline

• Lu-PSMA
• Pembrolizumab plus denosumab

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Australian and New Zealand Urogenital and Prostate Cancer Trials Group portfolio CI brief
• Australian and New Zealand Urogenital and Prostate Cancer Trials Group pipeline updates RSS

Related

• Sector hub: All tracked pharma companies